Islamabad : The Central Licensing Board of the Drug Regulatory Authority of Pakistan (DRAP) has approved local manufacturing of Chloroquine phosphate active pharmaceutical ingredient (API)—a drug used in management of SARS-CoV 2 infected patients. Chloroquine API can now be indigenously manufactured to meet the requirements of pharmaceutical companies who prepare Chloroquine phosphate tablets, injections and syrups.
A DRAP spokesperson said, backto b-ack expert committee meetings are being convened to evaluate the applications of various items including those of drug manufacturing, mechanical ventilators, convalescent plasma, and hand sanitizers. He added that the Clinical Study Committee of DRAP has allowed clinical trials for convalescent plasma for the purpose of passive immunization in current COVID-19 pandemic in Pakistan. The application was filed by Dr. Tahir Shamsi, Principle Investigator, Professor and Chairman of the National Institute of Blood Disease and Bone Marrow Transplantation, Karachi.
In this study, convalescent plasma from recovered COVID-19 patients would be injected to moderate and severe COVID-19 patients for the purpose of passive immunity for treatment, and to prevent these patients from going on to ventilators. The CSC has also approved clinical trial/test of basic ventilators, indigenously developed by the Pakistan Engineering Council.
People work at their stations at the National Incubation Centre . — AFP/FileIslamabad:The initiative financed by the...
This representational image shows children enjoy swings at a park in Islamabad. — INP/FileIslamabad:A Memorandum of...
Federal Minister for Maritime Affairs Qaisar Ahmed Sheikh addresses a press conference at PID on November 7, 2024. —...
Chairman Capital Development Authority Muhammad Ali Randhawa presides over a meeting. — APP/File Islamabad:Capital...
Azerbaijan ambassador Khazar Farhadov speaks at a victory day reception in Islamabad on November 7, 2023. —...
Coordinator to Prime Minister on Climate Change Romina Khurshid Alam addresses a press conference on the launch of new...